SLC2A1/GLUT1 expression in mural nodules of intraductal papillary mucinous neoplasm of the pancreas

Yasunori Oda, Shinichi Aishima, Koji Shindo, Minoru Fujino, yusuke mizuuchi, Masami Hattori, Tetsuyuki Miyazaki, Masao Tanaka, Yoshinao Oda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In intraductal papillary mucinous neoplasms (IPMNs), the presence of a mural nodule showing a papillary or nodular proliferation of tumor cells in the dilated pancreatic duct is an indication for resection of IPMN. Solute carrier family 2, facilitated glucose transporter member 1, known as glucose transporter type 1 (SLC2A1/GLUT1) mediates cellular glucose uptake in many carcinomas and is correlated with increased 18F-fluorodeoxyglucose (18F-FDG) uptake. We examined SLC2A1/GLUT1 expression in the mural nodules of 180 IPMN specimens to distinguish malignant/benign tumors. A mural nodule was detected in 80 (44.4%) of the IPMNs, and was detected in 18.6% (13/70) of the IPMN-low (dysplasia) specimens, 36.1% (13/36) of the IPMN-int, 93.3% (28/30) of the IPMN-high, and 59.1% (26/44) of the IPMN-inv (with an associated invasive carcinoma) specimens. The sensitivity for detecting mural nodules was 81.7% by endoscopic ultrasonography, 70% by contrast-enhanced computed tomography and 54% by endoscopic retrograde cholangiopancreatography. SLC2A1/GLUT1 expression in the mural nodules was recognized in the basal and basolateral cytomembrane of tumor cells and was expressed in 15.4% (2/13) of the IPMN-low, 15.4% (2/13) of the IPMN-int, 71.4% (20/28) of the IPMN-high and 84.6% (22/26) of the IPMN-inv groups. The SLC2A1/GLUT1 expression was significantly higher in the IPMN-high and IPMN-inv mural nodules than in those of the IPMN-low and IPMN-int groups. Our findings suggest that SLC2A1/GLUT1 is expressed late in the adenoma-carcinoma sequence during carcinogenesis in IPMN, and SLC2A1/GLUT1 act as therapeutic target for malignant IPMN.

Original languageEnglish
Pages (from-to)71-78
Number of pages8
JournalHuman Pathology
Volume65
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Pancreatic Neoplasms
Neoplasms
Carcinoma
Glucose Transporter Type 1
Endosonography
Facilitative Glucose Transport Proteins
Endoscopic Retrograde Cholangiopancreatography
Pancreatic Ducts
Fluorodeoxyglucose F18

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

SLC2A1/GLUT1 expression in mural nodules of intraductal papillary mucinous neoplasm of the pancreas. / Oda, Yasunori; Aishima, Shinichi; Shindo, Koji; Fujino, Minoru; mizuuchi, yusuke; Hattori, Masami; Miyazaki, Tetsuyuki; Tanaka, Masao; Oda, Yoshinao.

In: Human Pathology, Vol. 65, 01.07.2017, p. 71-78.

Research output: Contribution to journalArticle

Oda, Yasunori ; Aishima, Shinichi ; Shindo, Koji ; Fujino, Minoru ; mizuuchi, yusuke ; Hattori, Masami ; Miyazaki, Tetsuyuki ; Tanaka, Masao ; Oda, Yoshinao. / SLC2A1/GLUT1 expression in mural nodules of intraductal papillary mucinous neoplasm of the pancreas. In: Human Pathology. 2017 ; Vol. 65. pp. 71-78.
@article{8972684f72be48e1923989e89edd6036,
title = "SLC2A1/GLUT1 expression in mural nodules of intraductal papillary mucinous neoplasm of the pancreas",
abstract = "In intraductal papillary mucinous neoplasms (IPMNs), the presence of a mural nodule showing a papillary or nodular proliferation of tumor cells in the dilated pancreatic duct is an indication for resection of IPMN. Solute carrier family 2, facilitated glucose transporter member 1, known as glucose transporter type 1 (SLC2A1/GLUT1) mediates cellular glucose uptake in many carcinomas and is correlated with increased 18F-fluorodeoxyglucose (18F-FDG) uptake. We examined SLC2A1/GLUT1 expression in the mural nodules of 180 IPMN specimens to distinguish malignant/benign tumors. A mural nodule was detected in 80 (44.4{\%}) of the IPMNs, and was detected in 18.6{\%} (13/70) of the IPMN-low (dysplasia) specimens, 36.1{\%} (13/36) of the IPMN-int, 93.3{\%} (28/30) of the IPMN-high, and 59.1{\%} (26/44) of the IPMN-inv (with an associated invasive carcinoma) specimens. The sensitivity for detecting mural nodules was 81.7{\%} by endoscopic ultrasonography, 70{\%} by contrast-enhanced computed tomography and 54{\%} by endoscopic retrograde cholangiopancreatography. SLC2A1/GLUT1 expression in the mural nodules was recognized in the basal and basolateral cytomembrane of tumor cells and was expressed in 15.4{\%} (2/13) of the IPMN-low, 15.4{\%} (2/13) of the IPMN-int, 71.4{\%} (20/28) of the IPMN-high and 84.6{\%} (22/26) of the IPMN-inv groups. The SLC2A1/GLUT1 expression was significantly higher in the IPMN-high and IPMN-inv mural nodules than in those of the IPMN-low and IPMN-int groups. Our findings suggest that SLC2A1/GLUT1 is expressed late in the adenoma-carcinoma sequence during carcinogenesis in IPMN, and SLC2A1/GLUT1 act as therapeutic target for malignant IPMN.",
author = "Yasunori Oda and Shinichi Aishima and Koji Shindo and Minoru Fujino and yusuke mizuuchi and Masami Hattori and Tetsuyuki Miyazaki and Masao Tanaka and Yoshinao Oda",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.humpath.2017.03.008",
language = "English",
volume = "65",
pages = "71--78",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - SLC2A1/GLUT1 expression in mural nodules of intraductal papillary mucinous neoplasm of the pancreas

AU - Oda, Yasunori

AU - Aishima, Shinichi

AU - Shindo, Koji

AU - Fujino, Minoru

AU - mizuuchi, yusuke

AU - Hattori, Masami

AU - Miyazaki, Tetsuyuki

AU - Tanaka, Masao

AU - Oda, Yoshinao

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In intraductal papillary mucinous neoplasms (IPMNs), the presence of a mural nodule showing a papillary or nodular proliferation of tumor cells in the dilated pancreatic duct is an indication for resection of IPMN. Solute carrier family 2, facilitated glucose transporter member 1, known as glucose transporter type 1 (SLC2A1/GLUT1) mediates cellular glucose uptake in many carcinomas and is correlated with increased 18F-fluorodeoxyglucose (18F-FDG) uptake. We examined SLC2A1/GLUT1 expression in the mural nodules of 180 IPMN specimens to distinguish malignant/benign tumors. A mural nodule was detected in 80 (44.4%) of the IPMNs, and was detected in 18.6% (13/70) of the IPMN-low (dysplasia) specimens, 36.1% (13/36) of the IPMN-int, 93.3% (28/30) of the IPMN-high, and 59.1% (26/44) of the IPMN-inv (with an associated invasive carcinoma) specimens. The sensitivity for detecting mural nodules was 81.7% by endoscopic ultrasonography, 70% by contrast-enhanced computed tomography and 54% by endoscopic retrograde cholangiopancreatography. SLC2A1/GLUT1 expression in the mural nodules was recognized in the basal and basolateral cytomembrane of tumor cells and was expressed in 15.4% (2/13) of the IPMN-low, 15.4% (2/13) of the IPMN-int, 71.4% (20/28) of the IPMN-high and 84.6% (22/26) of the IPMN-inv groups. The SLC2A1/GLUT1 expression was significantly higher in the IPMN-high and IPMN-inv mural nodules than in those of the IPMN-low and IPMN-int groups. Our findings suggest that SLC2A1/GLUT1 is expressed late in the adenoma-carcinoma sequence during carcinogenesis in IPMN, and SLC2A1/GLUT1 act as therapeutic target for malignant IPMN.

AB - In intraductal papillary mucinous neoplasms (IPMNs), the presence of a mural nodule showing a papillary or nodular proliferation of tumor cells in the dilated pancreatic duct is an indication for resection of IPMN. Solute carrier family 2, facilitated glucose transporter member 1, known as glucose transporter type 1 (SLC2A1/GLUT1) mediates cellular glucose uptake in many carcinomas and is correlated with increased 18F-fluorodeoxyglucose (18F-FDG) uptake. We examined SLC2A1/GLUT1 expression in the mural nodules of 180 IPMN specimens to distinguish malignant/benign tumors. A mural nodule was detected in 80 (44.4%) of the IPMNs, and was detected in 18.6% (13/70) of the IPMN-low (dysplasia) specimens, 36.1% (13/36) of the IPMN-int, 93.3% (28/30) of the IPMN-high, and 59.1% (26/44) of the IPMN-inv (with an associated invasive carcinoma) specimens. The sensitivity for detecting mural nodules was 81.7% by endoscopic ultrasonography, 70% by contrast-enhanced computed tomography and 54% by endoscopic retrograde cholangiopancreatography. SLC2A1/GLUT1 expression in the mural nodules was recognized in the basal and basolateral cytomembrane of tumor cells and was expressed in 15.4% (2/13) of the IPMN-low, 15.4% (2/13) of the IPMN-int, 71.4% (20/28) of the IPMN-high and 84.6% (22/26) of the IPMN-inv groups. The SLC2A1/GLUT1 expression was significantly higher in the IPMN-high and IPMN-inv mural nodules than in those of the IPMN-low and IPMN-int groups. Our findings suggest that SLC2A1/GLUT1 is expressed late in the adenoma-carcinoma sequence during carcinogenesis in IPMN, and SLC2A1/GLUT1 act as therapeutic target for malignant IPMN.

UR - http://www.scopus.com/inward/record.url?scp=85021421716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021421716&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2017.03.008

DO - 10.1016/j.humpath.2017.03.008

M3 - Article

VL - 65

SP - 71

EP - 78

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -